Hormones and MS: Risk factors, biomarkers, and therapeutic targets
- PMID: 29307303
- DOI: 10.1177/1352458517737396
Hormones and MS: Risk factors, biomarkers, and therapeutic targets
Abstract
Sex differences in epidemiological, clinical, and pathological features of multiple sclerosis (MS) have been observed for decades, establishing a foundation for more recent progress in our understanding of their overall impact on the disease. In the ACTRIMS session on Hormones, Sex Chromosomes, and MS: Risk Factors, Biomarkers, and Therapeutic Targets, this progress was summarized in three presentations by pioneers in the field, revealing evidence that sex chromosomes, epigenetic factors, and sex hormones function as interactive determinants of disease risk and phenotype in a fashion dependent upon life stage, from prenatal development, childhood, and adolescence to adulthood and aging. Implications for the effects of puberty, pregnancy, menopause, and andropause on autoimmune and neurodegenerative mechanisms were discussed, along with potential applications of exogenous hormones. Although several limitations in current approaches and concepts were noted, current insights pave the way for future progress in our understanding of this enigmatic disease.
Keywords: Puberty; estrogen; menopause; pregnancy; testosterone.
Similar articles
-
The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis.Mult Scler. 2014 Apr;20(5):520-6. doi: 10.1177/1352458513519181. Epub 2014 Feb 21. Mult Scler. 2014. PMID: 24561324 Review.
-
Impact of sex hormones on immune function and multiple sclerosis development.Immunology. 2019 Jan;156(1):9-22. doi: 10.1111/imm.13004. Epub 2018 Oct 11. Immunology. 2019. PMID: 30222193 Free PMC article. Review.
-
The impact of menopause on multiple sclerosis.Autoimmun Rev. 2023 Aug;22(8):103363. doi: 10.1016/j.autrev.2023.103363. Epub 2023 May 23. Autoimmun Rev. 2023. PMID: 37230311 Review.
-
Gender issues in multiple sclerosis.Int Rev Neurobiol. 2007;79:377-92. doi: 10.1016/S0074-7742(07)79017-7. Int Rev Neurobiol. 2007. PMID: 17531851 Review.
-
Sexual disparities in the incidence and course of MS.Clin Immunol. 2013 Nov;149(2):201-10. doi: 10.1016/j.clim.2013.03.005. Epub 2013 Mar 22. Clin Immunol. 2013. PMID: 23608496 Review.
Cited by
-
Impact of Menopause in Patients with Multiple Sclerosis: Current Perspectives.Int J Womens Health. 2023 Jan 25;15:103-109. doi: 10.2147/IJWH.S334719. eCollection 2023. Int J Womens Health. 2023. PMID: 36721498 Free PMC article. Review.
-
Immunomodulatory Potential of Human Mesenchymal Stem Cells and their Exosomes on Multiple Sclerosis.Adv Pharm Bull. 2022 Mar;12(2):389-397. doi: 10.34172/apb.2022.038. Epub 2021 Feb 6. Adv Pharm Bull. 2022. PMID: 35620339 Free PMC article.
-
Clinical Characteristics of Early-Onset and Late-Onset Multiple Sclerosis in Patients from Lithuania.Medicina (Kaunas). 2025 Jan 13;61(1):107. doi: 10.3390/medicina61010107. Medicina (Kaunas). 2025. PMID: 39859088 Free PMC article.
-
Menopausal transition in multiple sclerosis: relationship with disease activity and brain volume measurements.Front Neurol. 2023 Aug 3;14:1251667. doi: 10.3389/fneur.2023.1251667. eCollection 2023. Front Neurol. 2023. PMID: 37602270 Free PMC article.
-
Human-Induced Pluripotent Stem Cell-Based Models for Studying Sex-Specific Differences in Neurodegenerative Diseases.Adv Exp Med Biol. 2022;1387:57-88. doi: 10.1007/5584_2021_683. Adv Exp Med Biol. 2022. PMID: 34921676 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical